Filters
Webcast: Covid-19: What it means to your clinic. Practice pearls for the Asian primary care physician.
The second HIV patient to successfully undergo stem cell transplantation is still in remission, a good 30 months after stopping antiretroviral therapy (ART) — raising hope that curing HIV is a possibility.
The novel rifabutin-based triple therapy (RHB-105) delivers promising outcomes as first-line empirical treatment for Helicobacter pylori eradication, according to the results of a phase III, double blind trial. This therapy addresses the challenge of rising antibiotic resistance in the current environment.
Men who have sex with men (MSM) who are on pre-exposure prophylaxis (PrEP) for HIV are at risk of hepatitis C virus (HCV) infections, a new study has found.
Frontline health workers caring for patients with the novel coronavirus disease (COVID-19) may benefit from effective interventions derived from previous emerging virus outbreaks, which can be employed to help mitigate psychological distress, suggest the results of a rapid review and meta-analysis.
A trial vaccine for the prevention of COVID-19 is underway with the first US participants being dosed in the Phase 1/2 clinical trial. Known as the BNT162 vaccine programme, the trials are a collaboration between Pfizer Inc. and BioNTech SE, and is part of a global development programme with Germany and the US taking the lead in having the first cohorts to be vaccinated. Germany started the study 1 week earlier.
A panel of ENT specialists came together online to discuss the aftershocks of the COVID-19 pandemic and what it means to clinicians and patients alike.
Singapore’s Ministry of Health (MOH) has confirmed 876 new cases of COVID-19 infection on May 10. Two casualties have been recorded on May 6, bringing the total COVID-19 deaths in the city-state to 20. Older age seems a common factor among them.
After months of work disruption, profound worrying, social distancing, and isolation, SARS-CoV-2* still rages on, unyielding to human interventions.
Use of the interleukin(IL)-1 inhibitor anakinra led to clinical improvements in patients with coronavirus disease (COVID)-19, acute respiratory distress syndrome (ARDS), and systemic inflammation who are under noninvasive ventilation outside the intensive care unit (ICU), an Italian retrospective study has shown.
